- 询价
- MedChemExpress(MCE)
- 美国
- HY-L066
- 2025年12月05日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
FDA Approved & Pharmacopeial Drug Library
MCE 国际站：FDA Approved & Pharmacopeial Drug Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.MCE owns a unique collection of 3358 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
Description & Advantages:
• A unique collection of 3358 marketed drugs for high throughput screening (HTS) and high content screening (HCS).
• All drugs were from approved institutions such as FDA, EMA, NMPA, PMDA, or pharmacopoeia such as USP, BP, EP, JP, etc.
• Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.
• A useful tool for researching new targets of marketed old drugs.
• Structurally diverse, bioactive, and cell permeable.
• More detailed compound information with structure, IC50, and brief introduction.
• NMR and HPLC validated ensure high purity.
• All compounds are in stock and continuously updated.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Fluorescein Diacetate (FDA ) 1. Place pollen on slide. 2. Incubate in humid chamber (wet Whatman in Tupperware) ~ 30 min. 3. Add drops of FDA (2mg/ml in acetone) to Pollen Growth Media (~/ml
Nature 综述导读：FDA 批准第 100 个抗体药物！抗体药物的研究方向在哪里？
人源化单克隆抗体成功转化到临床。在全球范围内，至少有 570 种治疗性单克隆抗体正在临床试验中，其中有 79 种治疗性单克隆抗体已获得美国 FDA 批准。图四 Journal of Biomedical Science (2020) 27:1自 1986 年的第一个获批单抗药物以来，FDA 直到 8 年后的 1994 年才批准第二种治疗性单克隆抗体产品。2013 年之前，每年也只有寥寥几个抗体获批上市，但是近十年以来，抗体的获批已慢慢开始变得稀松平常，平均每年约有 10 项批准。FDA 于 2015 年
Considerations When Submitting Nanotherapeutics to FDA/CDER for Regulatory Review
The Food and Drug Administration (FDA) does not, as yet, have specific guidances for products containing nanoscale materials. As announced in the report issued by the FDA Nanotechnology Task Force (July 2007
技术资料暂无技术资料 索取技术资料
